Fiona Nussey

Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial

Éric Pujade-Lauraine, Jonathan A. Ledermann, Frédèric Selle et al. · The Lancet Oncology · 2017 · 1.9K citations

Pharmacy, Oncology, Pharmacotherapy +14

Olaparib tablets as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a final analysis of a double-blind, randomised, placebo-controlled, phase 3 trial

Andrés Poveda, Anne Floquet, Jonathan A. Ledermann et al. · The Lancet Oncology · 2021 · 416 citations · Full text

Medicine, Oncology, Pharmacology +15

Molecular stratification of endometrioid ovarian carcinoma predicts clinical outcome

Robert L. Hollis, John P. Thomson, Bárbara Stanley et al. · Nature Communications · 2020 · 141 citations · Full text

Medicine, Oncology, Pathology +17

Impact of neutropenia on delivering planned adjuvant chemotherapy: UK audit of primary breast cancer patients

Robert Leonard, David Miles, Robert Thomas et al. · British Journal of Cancer · 2003 · 99 citations · Full text

Medicine, Oncology, Pharmacology +17

Patterns of clinicopathological features and outcome in epithelial ovarian cancer patients: 35 years of prospectively collected data

Aparna Irodi, Tzyvia Rye, Karl E. Herbert et al. · BJOG An International Journal of Obstetrics & Gynaecology · 2020 · 64 citations · Full text

Medicine, Gynecology, Oncology +14